Results 91 to 100 of about 1,252,032 (378)

Coronavirus biology and replication: implications for SARS-CoV-2

Nature Reviews Microbiology, 2020
The SARS-CoV-2 pandemic and its unprecedented global societal and economic disruptive impact has marked the third zoonotic introduction of a highly pathogenic coronavirus into the human population.
P. V’kovski, A. Kratzel, Silvio Steiner, H. Stalder, V. Thiel   +4 more
semanticscholar   +1 more source

Coronaviruses and SARS-COV-2

TURKISH JOURNAL OF MEDICAL SCIENCES, 2020
Coronaviruses (CoVs) cause a broad spectrum of diseases in domestic and wild animals, poultry, and rodents, ranging from mild to severe enteric, respiratory, and systemic disease, and also cause the common cold or pneumonia in humans. Seven coronavirus species are known to cause human infection, 4 of which, HCoV 229E, HCoV NL63, HCoV HKU1 and HCoV OC43,
Mustafa HASÖKSÜZ, Selcuk KILIÇ, Fahriye SARAÇ   +2 more
openaire   +4 more sources

Hospital admissions linked to SARS-CoV-2 infection in children and adolescents: cohort study of 3.2 million first ascertained infections in England [PDF]

, 2023
Objective To describe hospital admissions associated with SARS-CoV-2 infection in children and adolescents. Design Cohort study of 3.2 million first ascertained SARS-CoV-2 infections using electronic health care record data.
Brown, Katherine, Denaxas, Spiros, Du Pre, Pascale, Gonzalez-Izquierdo, Arturo, Gurdasani, Deepti, Johnson, Mae, Kanthimathinathan, Hari Krishnan, Lai, Alvina G, Mateen, Bilal A, Pagel, Christina, Pathan, Nazima, Ramnarayan, Padmanabhan, Selby, David, Tomlinson, Christopher, Vollmer, Sebastian, Wilde, Harrison   +15 more
core  

Circulating histones as clinical biomarkers in critically ill conditions

FEBS Letters, EarlyView.
Circulating histones are emerging as promising biomarkers in critical illness due to their diagnostic, prognostic, and therapeutic potential. Detection methods such as ELISA and mass spectrometry provide reliable approaches for quantifying histone levels in plasma samples.
José Luis García‐Gimenez, Juan Carlos Ruiz‐Rodríguez, Ricard Ferrer, Raquel Durá, Antonio Artigas, Iván Bajaña, David Bolado López de Andujar, Irene Cánovas‐Cervera, Adrián Ceccato, Luis Chiscano‐Camón, Elena Climent‐Martinez, Georgia García Fernández, Gemma Goma, Verónica Monforte, Beatriz Quevedo‐Sánchez, Adolf Ruiz‐Sanmartín, Antonio Sierra‐Rivera, Nieves Carbonell Monleón   +17 more
wiley   +1 more source

Aptamer‐based strategies against SARS‐CoV‐2 viruses

BMEMat, 2023
The COVID‐19 pandemic, caused by SARS‐CoV‐2, has seriously threatened human life and security in recent years and has had a serious impact on economic development. A range of strategies, including antibodies, small‐molecule agents and vaccines, have been
Yihao Huang, Ximing Chen, Jialu Zhang, Wenhai Tian, Siwen Liu, Rachel Chun‐Yee Tam, Chaoyong Yang, Yanling Song   +7 more
doaj   +1 more source

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

medRxiv, 2020
Summary Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated.
Juanjuan Zhao, Q. Yuan, Haiyan Wang, Wei Liu, X. Liao, Yingying Su, Xin Wang, Jing Yuan, Tingdong Li, Jin-xiu Li, Shen Qian, Congming Hong, Fuxiang Wang, Yingxia Liu, Zhaoqin Wang, Qing He, Zhiyong Li, B. He, Tianying Zhang, Yang Fu, S. Ge, Lei Liu, Jun Zhang, N. Xia, Zheng Zhang   +24 more
semanticscholar   +1 more source

SARS-CoV-2 and the Nucleus

International Journal of Biological Sciences, 2022
The ongoing COVID-19 pandemic is caused by an RNA virus, SARS-CoV-2. The genome of SARS-CoV-2 lacks a nuclear phase in its life cycle and is replicated in the cytoplasm. However, interfering with nuclear trafficking using pharmacological inhibitors greatly reduces virus infection and virus replication of other coronaviruses is blocked in enucleated ...
Chen, Mengqi, Ma, Yue, Chang, Wakam
openaire   +2 more sources

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

Molecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez, Asieh Naderi, Kim‐Tuyen Huynh‐Dam, Vitali Sikirzhytski, Ioulia Chatzistamou, Hippokratis Kiaris   +5 more
wiley   +1 more source

Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant

Clinical & Translational Immunology, 2021
Objectives The emergence of a SARS‐CoV‐2 variant with a point mutation in the spike (S) protein, D614G, has taken precedence over the original Wuhan isolate by May 2020.
Cheryl Yi‐Pin Lee, Siti Naqiah Amrun, Rhonda Sin‐Ling Chee, Yun Shan Goh, Tze‐Minn Mak, Sophie Octavia, Nicholas Kim‐Wah Yeo, Zi Wei Chang, Matthew Zirui Tay, Anthony Torres‐Ruesta, Guillaume Carissimo, Chek Meng Poh, Siew‐Wai Fong, Wang Bei, Sandy Lee, Barnaby Edward Young, Seow‐Yen Tan, Yee‐Sin Leo, David C Lye, Raymond TP Lin, Sebastien Maurer‐Stroh, Bernett Lee, Cheng‐I Wang, Laurent Renia, Lisa FP Ng   +24 more
doaj   +1 more source

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

Science, 2020
What happens next? Four months into the severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) outbreak, we still do not know enough about postrecovery immune protection and environmental and seasonal influences on transmission to predict ...
S. Kissler, C. Tedijanto, E. Goldstein, Y. Grad, M. Lipsitch   +4 more
semanticscholar   +1 more source